Screener
Arcus Biosciences RCUS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from maturities of marketable securities | 482 | 615 |
| Proceeds from sales of marketable securities | 16 | 69 |
| Purchases of property and equipment | — | (1) |
| Net cash provided by investing activities | 166 | 169 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock ($— and $14 from a related party) | — | 142 |
| Proceeds from debt issuances, net | — | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 19 | 3 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's investing cash flow?
- Arcus Biosciences (RCUS) reported investing cash flow of $52M in Q2 2026.
- How has Arcus Biosciences's investing cash flow changed year-over-year?
- Arcus Biosciences's investing cash flow decreased by 62.0% year-over-year, from $137M to $52M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Arcus Biosciences's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude